Pasithea Therapeutics posts investor presentation on PAS-004 MEK inhibitor program in NF1 and solid tumors

Reuters2026/07/21 15:53

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pasithea highlighted PAS-004, a next-generation macrocyclic MEK1/2 inhibitor, as its lead program for NF1 and MAPK-driven solid tumors.
Interim Phase 1 readout in advanced cancers: no dose-limiting toxicities; no ocular retinal abnormalities or cardiotoxicities; treatment-related AEs were Grade 1-2.
Pharmacokinetics showed an estimated ~60-hour half-life in humans; cohort 7 Cmax and Cmin exceeded the cellular IC50, supporting once-daily dosing.
Early efficacy signal: partial response in a MEK-rechallenged patient with a BRAF V600E-mutated tumor; patient remained on study at 11 months.
Development plan centers on adult NF1 plexiform neurofibromas with interim results targeted for 2H 2026; management sized NF1-PN at $2+ billion TAM.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pasithea Therapeutics posts investor presentation on PAS-004 MEK inhibitor program in NF1 and solid tumors

You may also like

Crypto prices